Dechra increases its 2018 full year dividend by 18.9%
Dechra Pharmaceuticals 2018 final results
Strong financial performance:
Revenue growth of 13.9% to £407.1 million.
Underlying operating profit growth of 24.0% to £99.2 million.
Underlying EBIT margin expansion of 200 bps to 24.4%.
Underlying diluted EPS increased by 20.9% to 76.45 pence.
Full year dividend of 25.50 pence, up 18.9%.
Shoe Zone 2018 final results
Avon Rubber 2018 final resultsRead more
Workspace 2019 interim resultsRead more
B&M European value retail 2019 interim resultsRead more
Land Securities 2018 interim resultsRead more
Adept technology 2019 interim resultsRead more
Softcat 2018 final resultsRead more
Bellway 2018 final resultsRead more
Ferguson 2018 Final resultsRead more